<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: The disodium disuccinate derivative of astaxanthin (DDA) is a <z:chebi fb="2" ids="23044">carotenoid</z:chebi> <z:chebi fb="11" ids="22586">antioxidant</z:chebi> under development for the treatment of ischemic cardiovascular events </plain></SENT>
<SENT sid="1" pm="."><plain>Recent evidence suggests that reactive oxygen species (ROS) play an important role in platelet activation </plain></SENT>
<SENT sid="2" pm="."><plain>This study seeks to investigate the effects of a reactive oxygen species quencher, DDA, in a canine model of carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: After formation of an occlusive carotid <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, dogs were administered recombinant tissue plasminogen activator intra-arterially to achieve thrombolysis in the presence of either 0.9% <z:chebi fb="1" ids="26710">NaCl</z:chebi> solution or DDA (10-50 mg/kg i.v </plain></SENT>
<SENT sid="4" pm="."><plain>infusion) </plain></SENT>
<SENT sid="5" pm="."><plain>Ex vivo platelet aggregation and tongue <z:mp ids='MP_0001914'>bleeding</z:mp> times were measured before and after drug administration </plain></SENT>
<SENT sid="6" pm="."><plain>Residual <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> mass was analyzed at the end of each experiment </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The data indicated a dose- dependent reduction in the incidence of carotid artery rethrombosis </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, platelet aggregation and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weights were dose-dependently inhibited by DDA </plain></SENT>
<SENT sid="9" pm="."><plain>No change was recorded in tongue <z:mp ids='MP_0001914'>bleeding</z:mp> time among the treatment groups </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The data demonstrate that at the doses used in this study, DDA significantly reduced the incidence of secondary <z:mp ids='MP_0005048'>thrombosis</z:mp> while maintaining <z:mpath ids='MPATH_458'>normal</z:mpath> hemostasis </plain></SENT>
<SENT sid="11" pm="."><plain>The results suggest that upon further study, DDA may one day find utility in revascularization procedures </plain></SENT>
</text></document>